334929-99-6

Basic information

• Product Name: 5-FLUORO-2-(2,2,2-TRIFLUOROETHOXY)ANILINE
• Synonyms: 5-FLUORO-2-(2,2,2-TRIFLUOROETHOXY)ANILINE;5-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenylamine
• CAS NO: 334929-99-6
• Molecular Formula: C₈H₇F₄NO
• Molecular Weight: 209.14
• Mol File: 334929-99-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-FLUORO-2-(2,2,2-TRIFLUOROETHOXY)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-FLUORO-2-(2,2,2-TRIFLUOROETHOXY)ANILINE(334929-99-6)
• EPA Substance Registry System: 5-FLUORO-2-(2,2,2-TRIFLUOROETHOXY)ANILINE(334929-99-6)

Safety Data

• Hazardous Substances Data: 334929-99-6(Hazardous Substances Data)

Upstream product

• 334929-98-5 5-Fluoro-2-(2,2,2-trifluoroethoxy)-nitrobenzene 
• 7440-02-0 nickel 

Downstream Products

• 334930-00-6 1-[5-Fluoro-2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 

Relevant articles and documents

ADRENERGIC RECEPTOR ANTAGONISTS

The present invention relates to α1a and/or α1b adrenergic receptor antagonists, which can be used to treat a disease or disorder mediated through α1a and/or α1b adrenergic receptors. Compounds and pharmaceutical compositions disclosed herein can be used to treat benign prostatic hyperplasia (BPH) and related symptoms thereof. Further, such compounds can be used to treat lower urinary tract symptoms that may or may not be associated with BPH. The present invention also relates to processes to prepare the disclosed compounds, pharmaceutical compositions thereof, and methods of treating BPH or related symptoms thereof.

BENZOPYRAN DERIVATIVES

Benzopyran derivatives (I) (R = phenyl, alkoxycarbonyl, alkylcarbonyl, CONH2, CONH(alkyl), CON(alkyl)2, CN or alkoxycarbonylamino; R2 = alkyl, alkoxy, polyfluoroalkoxy, OH or CF3SO2O; each of R4 and R5 independently = H, halogen, polyfluoroalkyl, polyfluo

Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor

Described are derivatives with an adrenergic antagonistic activity and, in particular, high selectivity for α1a- and α1d-adrenergic receptors compared to α1b-receptors. This selectivity profile suggests the use of these de